BioSpecifics Technologies Corp. Announces Presentation of Interim Data from Phase 1 Study of CCH for the Treatment of Uterine Fibroids at 65th Annual Scientific Meeting of the Society for Reproductive Investigation
- Category: Proteins and Peptides
- Published on Tuesday, 13 March 2018 12:15
- Hits: 468
LYNBROOK, NY, USA I March 12, 2018 I BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced the presentation of interim data from its ongoing Phase 1 trial of Collagenase Clostridium Histolyticum (CCH) for the treatment of uterine fibroids at the 65th Annual Scientific Meeting of the Society for Reproductive Investigation on Friday, March 9, 2018 in San Diego, CA. The data show the safety and effectiveness of the CCH injection method in five patients.
"These interim data are very encouraging and show not only a significant reduction of collagen content but also the disruption of the tissue pattern in the uterine fibroids injected with CCH," said Thomas L. Wegman, President of BioSpecifics. "Although uterine fibroids are the most prevalent tumor of the female reproductive tract, non-surgical treatments are extremely limited and this is the first trial assessing the treatment of uterine fibroids using injectable collagenase. We believe there are strong benefits to a treatment that can effectively reduce the size and stiffness of the fibroids which will ultimately decrease symptoms of pain and bleeding, avoid the need for surgical procedures and result in a better quality of life for these affected women."
Three patients were injected with CCH and underwent a hysterectomy 24-96 hours after the injection. Two patients subsequently were injected with a higher dose of collagenase, and underwent a hysterectomy 63 days after the injection. The collagenase-treated tissue samples showed not only a significant reduction of collagen content but also the disruption of the tissue pattern, while in control tissues the collagen remained abundant and compact. The digestion of collagen did not extend beyond the capsule of any fibroid. No adverse event occurred in these patients.
The Phase 1 open-label dose escalation study is being conducted at the Department of Gynecology & Obstetrics at Johns Hopkins University and will enroll a total of 15 female subjects treated prior to hysterectomy. The primary endpoint will assess the safety and tolerability of a single injection of XIAFLEX directly into the uterine fibroids at three doses under transvaginal ultrasound guidance. The secondary endpoints will assess symptoms of pain and bleeding, quality of life throughout the study, shrinkage of XIAFLEX treated fibroids in size, increased rates of apoptosis in treated fibroids and a decrease in the collagen content of treated fibroids.
About Uterine Fibroids
Uterine fibroids are very common benign tumors in the reproductive tract that contain large amounts of collagen which may cause pelvic discomfort and pain, decreased fertility, pregnancy complications, an increased rate of miscarriage, uterine bleeding, prolonged menstrual bleeding and frequent urination. Uterine fibroids are the leading cause of hysterectomies in the U.S., accounting for about 250,000 hysterectomies and 30,000 myomectomies performed each year. Uterine fibroids have been estimated to cost up to $9.4 billion annually in direct costs in the U.S. and there is a high level of recurrence with current treatment options.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for thirteen clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren's contracture and for Peyronie's disease in Europe and Australia. The CCH research and development pipeline includes several additional promising indications. BioSpecifics is managing the development of CCH for uterine fibroids and is conducting a Phase 1 clinical trial. For more information, please visit www.biospecifics.com.
SOURCE: BioSpecifics Technologies